| First Author | Yu TY | Year | 2015 |
| Journal | PLoS One | Volume | 10 |
| Issue | 1 | Pages | e0117112 |
| PubMed ID | 25615839 | Mgi Jnum | J:245030 |
| Mgi Id | MGI:5913809 | Doi | 10.1371/journal.pone.0117112 |
| Citation | Yu TY, et al. (2015) Aryl hydrocarbon receptors in osteoclast lineage cells are a negative regulator of bone mass. PLoS One 10(1):e0117112 |
| abstractText | Aryl hydrocarbon receptors (AhRs) play a critical role in various pathological and physiological processes. Although recent research has identified AhRs as a key contributor to bone metabolism following studies in systemic AhR knockout (KO) or transgenic mice, the cellular and molecular mechanism(s) in this process remain unclear. In this study, we explored the function of AhR in bone metabolism using AhR(RANKDeltaOc/DeltaOc) (RANK(Cre/+);AhR(flox/flox)) mice. We observed enhanced bone mass together with decreased resorption in both male and female 12 and 24-week-old AhR(RANKDeltaOc/DeltaOc) mice. Control mice treated with 3-methylcholanthrene (3MC), an AhR agonist, exhibited decreased bone mass and increased bone resorption, whereas AhR(CtskDeltaOc/DeltaOc) (Ctsk(Cre/+);AhR(flox/flox)) mice injected with 3MC appeared to have a normal bone phenotype. In vitro, bone marrow-derived macrophages (BMDMs) from AhR(RANKDeltaOc/DeltaOc) mice exhibited impaired osteoclastogenesis and repressed differentiation with downregulated expression of B lymphocyte-induced maturation protein 1 (Blimp1), and cytochrome P450 genes Cyp1b1 and Cyp1a2. Collectively, our results not only demonstrated that AhR in osteoclast lineage cells is a physiologically relevant regulator of bone resorption, but also highlighted the need for further studies on the skeletal actions of AhR inhibitors in osteoclast lineage cells commonly associated with bone diseases, especially diseases linked to environmental pollutants known to induce bone loss. |
